TRIAZOLAM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Triazolam, and when can generic versions of Triazolam launch?
Triazolam is a drug marketed by Hikma, Mylan Pharms Inc, Novast Labs, Sandoz, Watson Labs, and Zydus Pharms. and is included in six NDAs.
The generic ingredient in TRIAZOLAM is triazolam. There are six drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the triazolam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Triazolam
A generic version of TRIAZOLAM was approved as triazolam by NOVAST LABS on October 20th, 2020.
Summary for TRIAZOLAM
US Patents: | 0 |
Applicants: | 6 |
NDAs: | 6 |
Finished Product Suppliers / Packagers: | 7 |
Raw Ingredient (Bulk) Api Vendors: | 37 |
Clinical Trials: | 19 |
Patent Applications: | 4,083 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TRIAZOLAM |
What excipients (inactive ingredients) are in TRIAZOLAM? | TRIAZOLAM excipients list |
DailyMed Link: | TRIAZOLAM at DailyMed |
Recent Clinical Trials for TRIAZOLAM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
RenJi Hospital | Phase 4 |
University of Manitoba | N/A |
Rocky Vista University, LLC | Phase 4 |
Pharmacology for TRIAZOLAM
Drug Class | Benzodiazepine |